Riogin, a Charlottesville, VA-based company that provides solutions to solve issues related to peptide therapeutics, raised a funding from CIT GAP Funds.
The amount of the funding was not disclosed.
The company intends to use the funds to add an additional senior technical person to the team, which will increase in-house assay capability and help scale the business.
Led by CEO Dr. Mario Geysen, Riogin focuses on improving the performance of peptide therapeutics (which suffer from issues related to short half-lives, inconvenient frequency of dosing and administration, and undesirable side-effects) through the production of new, safer drugs requiring less frequent administration.
FinSMEs
17/04/2014